Plasma homovanillic acid, plasma anti-D1 and -D2 dopamine-receptor activity, and negative symptoms in chronically mediated schizophrenia

Biol Psychiatry. 1992 Feb 15;31(4):357-64. doi: 10.1016/0006-3223(92)90229-s.

Abstract

We have investigated the relationship between the concentration of homovanillic acid in human plasma (pHVA) and plasma anti-D1 and anti-D2 dopamine receptor activity in chronic schizophrenic patients whose neuroleptic dosage was changed. The change in pHVA level correlated with that in anti-D1, not anti-D2 activity, thus suggesting that the neuroleptic-induced changes in pHVA concentration may be associated with the blocking of D1- as well as D2- receptors. The change of scores on the Scale for the Assessment of Negative Symptoms did not significantly correlate with changes in anti-D1 or anti-D2 activity, but did so correlated with the change in pHVA level.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antipsychotic Agents / therapeutic use*
  • Brain / drug effects
  • Dose-Response Relationship, Drug
  • Female
  • Hospitalization
  • Humans
  • Male
  • Middle Aged
  • Psychiatric Status Rating Scales*
  • Receptors, Dopamine / drug effects*
  • Receptors, Dopamine D1
  • Receptors, Dopamine D2
  • Schizophrenia / blood
  • Schizophrenia / drug therapy*
  • Schizophrenic Psychology*

Substances

  • Antipsychotic Agents
  • Receptors, Dopamine
  • Receptors, Dopamine D1
  • Receptors, Dopamine D2